Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Renal and Cardiovascular Effect of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibition in Combination With Loop Diuretics in Diabetic Patients With Chronic Heart Failure

Trial Profile

Renal and Cardiovascular Effect of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibition in Combination With Loop Diuretics in Diabetic Patients With Chronic Heart Failure

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Dec 2018

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Chronic heart failure; Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Proof of concept
  • Acronyms RECEDE-CHF
  • Most Recent Events

    • 16 Dec 2018 Planned primary completion date changed from 1 Nov 2018 to 31 Dec 2018.
    • 19 Sep 2018 Status changed from recruiting to active, no longer recruiting.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top